NCT06776679View on ClinicalTrials.gov

A Study of How [14C]-BGB-16673 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 24, 2025

Primary Completion Date

March 27, 2025

Study Completion Date

March 27, 2025

Conditions
Healthy Volunteers
Interventions
DRUG

[14C]-BGB-16673

Administered orally as suspension in lipid vehicle

Trial Locations (1)

53704-2526

Fortrea Clinical Research Unit Inc, Madison

Sponsors

Lead Sponsor

BeiGene
All Listed Sponsors
lead

BeiGene

INDUSTRY

NCT06776679 - A Study of How [14C]-BGB-16673 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Participants | Biotech Hunter | Biotech Hunter